search
Back to results

Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Lunch and Dinner in T2D (SkippB-T2D)

Primary Purpose

Breakfast

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Skipping Breakfast
Eating Breakfast
Sponsored by
Tel Aviv University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breakfast focused on measuring Skipping Breakfast

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • T2D since < 10 yrs, with HbA1c > 7 % and BMI: 26-34 kg/m2.
  • Only naïve or treated with oral antidiabetic drugs and with anti-hypertensive and lipid-lowering medication will be included.
  • Those treated with insulin or GLP-1 analogs or having major liver, heart or kidney illnesses will be excluded.

Exclusion Criteria:

  1. Type 1 DM, secondary DM, gestational DM
  2. Patients using insulin, TZDs
  3. Patients using corticosteroid, herb medication or other medications affecting glucose tolerance
  4. Renal dysfunction (Cr > 1.5mg/dL)
  5. Hepatic dysfunction (LFT > x 3UNL)
  6. Anemia (Hg > 10g/dL)
  7. Ischemic heart disease, congestive heart failure
  8. Severe diabetic complication (CRF, CVA, PDR, gastroparesis)
  9. Infectious disease
  10. Malignancy
  11. Pregnant women

Sites / Locations

  • Diabetes Unit E. Wolfson Medical centerRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Skipping Breakfast (NoB)

Eating Breakfast (YesB):

Arm Description

The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals

The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner

Outcomes

Primary Outcome Measures

Measure of plasma glucose
Postprandial glycemia

Secondary Outcome Measures

Measure of plasma Insulin
Measure of plasma GLP-1
Measure of free fatty acids (FFA)

Full Information

First Posted
November 2, 2014
Last Updated
June 2, 2015
Sponsor
Tel Aviv University
search

1. Study Identification

Unique Protocol Identification Number
NCT02287103
Brief Title
Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Lunch and Dinner in T2D
Acronym
SkippB-T2D
Official Title
Effect of Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Subsequent Isocaloric Lunch and Dinner in Type 2 Diabetic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Unknown status
Study Start Date
April 2015 (undefined)
Primary Completion Date
September 2015 (Anticipated)
Study Completion Date
November 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tel Aviv University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: Skipping breakfast and/or overeating at evening, has been associated in type 2 diabetic (T2D) individuals, with higher BMI, visceral adiposity, hyperlipidemia, increased overall postprandial glycemia (PPHG) and higher HbA1c. The absence of breakfast is also associated with increased plasma free fatty acids (FFA) along the morning until lunch. High plasma FFA in turn are triggering factor of insulin resistance, by inhibiting insulin mediated glucose uptake in obese and T2D subjects The investigators therefore hypothesize that compared to eating breakfast the prolonged overnight fasting caused by the breakfast omission will result in increased postprandial glycemic response after subsequent isocaloric lunch and dinner in T2D individuals. Objectives: With this aim will study T2D patients in randomized crossover design to consume in two separate days, either 3 standard isocaloric meals: Yes Breakfast condition (YesB) or omit breakfast: no breakfast condition (NoB) and consume only lunch and dinner with the same caloric content. Methods and Study Design: The YesB intervention will consist on three identical meals coating 700 Kcal each: breakfast at 8:00, lunch at 13:00 and dinner at 19:00. The NoB intervention the breakfast will be omitted and the subject continue fasting until lunch. Then the participants will consume identical 700 kcal Lunch at 13:00 and 700 Kcal dinners at 19:00. The investigators will assess plasma glucose, insulin, C-peptide, GLP-1 and FFA with blood samples collected every 30 min up to 180 min after breakfast, lunch and dinner and at the same time point the blood samples will be collected after 8:00 when the breakfast will be omitted. Expected results: The investigators expect that compared to NoB condition, in the YesB condition the postprandial response after lunch and dinner will be reduced for glucose and for FFA, while plasma insulin, C-peptide and GLP-1 postprandial response after lunch and dinner will be enhanced
Detailed Description
Background or Rationale Studies analyzing the postprandial glycemic response have shown that glucose tolerance display a clear diurnal variation with a progressive decline in carbohydrate tolerance toward the evening hours with more prolonged and higher postprandial glycemic response in the evening than in the morning. Meal timing patterns, on the other hand, exerts strong entraining influence on clock gene regulation of hormones and enzymes i.e. insulin, GLP-1, involved in glucose metabolism and postprandial glycemia disrupting the diurnal variation of postprandial glycemia (PPG). It suggests the extent of post-prandial rise in plasma glucose depends not only upon the quantity and nature of food ingested, and on the clock gene regulated circadian hormonal rhythms, it also depends upon the metabolic state immediately prior to eating. Indeed, meal schedule non-aligned with the clock gene circadian rhythms, such as skipping breakfast and/or overeating at evening, has been associated, in T2D individuals, with higher BMI, visceral adiposity, hyperlipidemia, higher HbA1c and increased PPG despite same caloric intake. The absence of breakfast has been associated in obese and T2D subjects with increased plasma levels of free fatty acids (FFA) along the morning until the lunch, Chronic and acute increase of FFA plasma levels, has been reported as triggering factor of insulin resistance, by inhibition of insulin mediated stimulated glucose uptake and/or phosphorylation which develops 3-4 hours after raising of plasma FFA and by inhibition of glycogen synthase, the rate limiting enzyme of glycogen synthesis, which develops 4-6 hours after the rise of FFA. However the effect of eating vs skipping breakfast on postprandial glucose response after identical lunch and dinner has not been explored. It is therefore important to explore the influence of eating versus skipping breakfast on postprandial glucose, after lunch and dinner in T2D individuals. Concomitantly the investigators will assess after lunch and dinner plasma insulin, GLP-1 and FFA response after lunch and dinner in T2D individuals. Expected results: The investigators expect that compared skipping breakfast condition, the eating breakfast condition will reduce postprandial plasma glucose and FFA response after lunch and dinner, while plasma insulin, C-peptide and GLP-1 after lunch and dinner will be enhanced Relevance of the study: If our hypothesis is confirmed it may be may be of practical benefit to people with Type 2 diabetes, a condition in which the reduction of PPHG at lunch and at dinner may result in improved HbA1c and might be also preventive of the risk for CVD Objectives: With this aim will study T2D patients in randomized crossover design to consume in two separate days, either 3 standard isocaloric meals: Yes Breakfast condition (YesB) or omit breakfast: no breakfast condition (NoB) and consume only lunch and dinner with the same caloric content. Methods and Study Design: The YesB intervention will consist on three identical meals coating 700 Kcal each: breakfast at 8:00, lunch at 13:00 and dinner at 19:00. The NoB intervention the breakfast will be omitted and the subject continue fasting until lunch. Then the participants will consume identical 700 kcal Lunch at 13:00 and 700 Kcal dinners at 19:00. The investigators will assess plasma glucose, insulin, C-peptide, GLP-1 and FFA with blood samples collected every 30 min up to 180 min after breakfast, lunch and dinner and at the same time point the blood samples will be collected after 8:00 when the breakfast will be omitted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breakfast
Keywords
Skipping Breakfast

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Skipping Breakfast (NoB)
Arm Type
Experimental
Arm Description
The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals
Arm Title
Eating Breakfast (YesB):
Arm Type
Active Comparator
Arm Description
The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner
Intervention Type
Other
Intervention Name(s)
Skipping Breakfast
Other Intervention Name(s)
omitting breakfast
Intervention Description
NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
Intervention Type
Other
Intervention Name(s)
Eating Breakfast
Intervention Description
YesB: will eat all three meals
Primary Outcome Measure Information:
Title
Measure of plasma glucose
Description
Postprandial glycemia
Time Frame
5 weeks
Secondary Outcome Measure Information:
Title
Measure of plasma Insulin
Time Frame
5 weeks
Title
Measure of plasma GLP-1
Time Frame
5 weeks
Title
Measure of free fatty acids (FFA)
Time Frame
5 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: T2D since < 10 yrs, with HbA1c > 7 % and BMI: 26-34 kg/m2. Only naïve or treated with oral antidiabetic drugs and with anti-hypertensive and lipid-lowering medication will be included. Those treated with insulin or GLP-1 analogs or having major liver, heart or kidney illnesses will be excluded. Exclusion Criteria: Type 1 DM, secondary DM, gestational DM Patients using insulin, TZDs Patients using corticosteroid, herb medication or other medications affecting glucose tolerance Renal dysfunction (Cr > 1.5mg/dL) Hepatic dysfunction (LFT > x 3UNL) Anemia (Hg > 10g/dL) Ischemic heart disease, congestive heart failure Severe diabetic complication (CRF, CVA, PDR, gastroparesis) Infectious disease Malignancy Pregnant women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Daniela Jakubowicz, MD
Phone
972508105552
Email
daniela.jak@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Julio Wainstein, MD
Phone
972506296940
Email
vainstein@wolfson.health.gov.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniela Jakubowicz, MD
Organizational Affiliation
Diabetes Unit E. Wolfson Medical center Holon, Tel Aviv Israe
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetes Unit E. Wolfson Medical center
City
Holon
State/Province
Tel Aviv
ZIP/Postal Code
58100
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniela Jakubowicz, MD
Phone
972508105552
Email
daniela.jak@gmail.com
First Name & Middle Initial & Last Name & Degree
Julio Wainstein, MD
Phone
97254522296
Email
vainstein@wolfson.health.gov.il
First Name & Middle Initial & Last Name & Degree
Daniela Jakubowicz, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
33512717
Citation
Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, Zaman S, Salmasi AM, Tsilidis K, Dehghan A. Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2021 Jan 29;1(1):CD013496. doi: 10.1002/14651858.CD013496.pub2.
Results Reference
derived

Learn more about this trial

Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Lunch and Dinner in T2D

We'll reach out to this number within 24 hrs